Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast Spray, a wound-healing agent; Ebrantil, an anti-dysuria agent; Ecclock gel for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, urinary stone dissolution and elimination acceleration agent for cattle. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; ART-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; ART-648, which is in phase II clinical trial for the treatment of bullous pemphigoid; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; and NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.